(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(-0.43%) $83.49
(-1.16%) $1.619
(-0.03%) $2 346.60
(0.91%) $27.50
(0.38%) $925.60
(0.27%) $0.934
(0.40%) $11.00
(0.09%) $0.800
(0.00%) $92.17
Live Chart Being Loaded With Signals
U.S. Stem Cell, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of autologous cellular therapies for the treatment of chronic and acute heart damage, and vascular and autoimmune diseases in the United States...
Stats | |
---|---|
本日の出来高 | 4.00 |
平均出来高 | 7 796.00 |
時価総額 | 64 151.00 |
EPS | $-0.000960 ( 2022-12-30 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.0100 |
ATR14 | $0 (0.00%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2022-04-25 | Knutson Gregory | Buy | 2 500 000 | Common Stock |
2022-03-18 | Knutson Gregory | Buy | 25 000 000 | Common Stock |
2022-02-24 | Knutson Gregory | Buy | 12 500 000 | Warrant |
2022-02-24 | Knutson Gregory | Buy | 12 500 000 | Convertible promissory Note (right to buy) |
2021-03-23 | Murphy William P Jr | Buy | 7 518 797 | Common Stock |
INSIDER POWER |
---|
100.00 |
Last 99 transactions |
Buy: 237 671 429 | Sell: 625 000 |
U.S. Stem Cell, Inc. 相関
10 最も正の相関 |
---|
10 最も負の相関 |
---|
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
U.S. Stem Cell, Inc. 財務諸表
Annual | 2022 |
収益: | $82 049.00 |
総利益: | $58 282.00 (71.03 %) |
EPS: | $-0.00560 |
FY | 2022 |
収益: | $82 049.00 |
総利益: | $58 282.00 (71.03 %) |
EPS: | $-0.00560 |
FY | 2021 |
収益: | $200 749 |
総利益: | $148 719 (74.08 %) |
EPS: | $-0.00800 |
FY | 2020 |
収益: | $277 087 |
総利益: | $212 970 (76.86 %) |
EPS: | $-0.00673 |
Financial Reports:
No articles found.
U.S. Stem Cell, Inc.
U.S. Stem Cell, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of autologous cellular therapies for the treatment of chronic and acute heart damage, and vascular and autoimmune diseases in the United States. The company's lead product candidates include MyoCell, a clinical therapy designed to populate regions of scar tissue within a patient's heart with autologous muscle cells or cells from a patient's body for enhancing cardiac function in chronic heart failure patients; and AdipoCell, a patient-derived cell therapy for the treatment of acute myocardial infarction, chronic heart ischemia, and lower limb ischemia. Its product development pipeline includes MyoCell SDF-1, an autologous muscle-derived cellular therapy for improving cardiac function in chronic heart failure patients. The company is also developing MyoCath, a deflecting tip needle injection catheter that is used to inject cells into cardiac tissue in therapeutic procedures to treat chronic heart ischemia and congestive heart failure. In addition, it provides physician and patient based regenerative medicine/cell therapy training, cell collection, and cell storage services; and cell collection and treatment kits for humans and animals, as well as operates a cell therapy clinic to provide cellular treatments for patients afflicted with neurological, autoimmune, orthopedic, and degenerative diseases. The company was formerly known as Bioheart, Inc. and changed its name to U.S. Stem Cell, Inc. in October 2015. U.S. Stem Cell, Inc. was incorporated in 1999 and is headquartered in Sunrise, Florida.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。